Experimental and Clinical Research Center (ECRC)

As a joint institution of the Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, the Experimental and Clinical Research Center (ECRC) provides the scientific and technical infrastructure, expertise and resources for translational research, including clinical trials, according to competitive criteria. The ECRC provides access to highly advanced technologies, such as ultra high field magnetic resonance imaging, and has a cleanroom laboratory for the production of immunotherapeutic vaccines and a unique infrastructure for patient-centered research in the form of a clinical pharmacology unit in accordance with the American “clinical research center” model. Studies with outpatients can be carried out in specialized university outpatient clinics. If a clinical trial requires hospitalization of the trial participant for several days, this can be provided in the inpatient hospital sites of the Charité.
The aim is to transform findings from basic research into clinical practice to improve the diagnosis, prevention and treatment of the most prevalent diseases in our society (cardiovascular and metabolic diseases, cancer, neurological disorders). An important aspect of the ECRC strategy is to facilitate extensive collaboration and communication between basic scientists and clinical researchers, thus creating a common platform as the basis for successful cooperation.

Berlin Institute of Health (BIH)
Translational research – the transfer of research results from bench to bedside – is also the mission of the Berlin Institute of Health (BIH). It focuses on the comprehensive approach of systems medicine and works closely together with the Max Delbrück Center. The Käthe-Beutler-Haus with laboratory and office space for scientific infrastructure and for biomedical and clinical research groups opened for the BIH at the Buch site in 2021. BIH, Charité and the Max Delbrück Center jointly use innovative technologies here and drive translational biomedical projects forward in order to develop new approaches for personalized medicine and novel therapies for chronic diseases.
News research
Towards understanding tumors in 3D
Researchers in Nikolaus Rajewsky’s lab at Max Delbrück Center combined high-resolution, single-cell spatial technologies to map a tumor’s cellular neighborhoods in 3D and identify potential targets fo...
more ...Max Delbrück Center to host Helmholtz Drug Discovery meeting
Top scientists and companies will meet in Berlin-Buch for the 2025 Helmholtz Drug Discovery Conference from April 28-30 to discuss RNA drugs, PROTACs, AI in drug discovery, and chemoproteomics and to ...
more ...Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical compan...
more ...Events Campus
23.05.2025, 09:00
WEITERBILDUNGSTAG LABOR 4.0 FÜR TECHNISCHE ANGESTELLTE UND LABORANT*INNEN
28.05.2025, 17:00
Campus Konzert Reihe – “Musik trifft Wissenschaft”
Werke von Bach, Gershwin und Bruch mit den Musikern Paul und Michael Afonin und Einblicken in das „Protein-Universum in uns“ von Dr. Fabian Coscia vom Max Delbrück Center
more ...